Ali Khalifa1, Don C Rockey2. 1. Department of Internal Medicine, Medical University of South Carolina, Charleston, South Carolina. 2. Department of Internal Medicine, Medical University of South Carolina, Charleston, South Carolina. Electronic address: rockey@musc.edu.
Abstract
BACKGROUND: Lower gastrointestinal bleeding (LGIB) is a common clinical problem, and may be more prevalent among patients with cirrhosis, especially in the setting of portal hypertension and coagulopathy. However, there is extremely little data available on the subject of LGIB in patients with cirrhosis. Therefore, the primary objective of this study was to better understand the etiology and outcomes of cirrhotic patients hospitalized with LGIB. MATERIALS AND METHODS: We analyzed 3,735 cirrhotic patients admitted to the Medical University of South Carolina between January 2011 and September 2018, and identified patients admitted with a primary diagnosis of hematochezia or bright red blood per rectum. RESULTS: Thirty patients with cirrhosis and LGIB were included in the cohort. The mean age was 56 ± 13 years, with 30% women. The mean model of end stage liver disease score was 22, and Child-Pugh (CP) scores were C: 41%, B: 33% and A: 26%. The mean Charlson Comorbidity Index was 5.6. Twenty-four (80%) patients had a clinical decompensating event (hepatic encephalopathy, ascites, esophageal varices); the mean hepatic venous pressure gradient was 14.1 mm Hg (n = 8). In 33% of patients, LGIB was considered significant bleeding that necessitated blood transfusion. The most common cause of LGIB was hemorrhoids (11 patients, 37%), followed by portal hypertensive enteropathy or colopathy (7 patients, 23%). Hemoglobin levels on admission were lower in patients with CP B/C cirrhosis than in those with CP A (P < 0.001). The length of stay was 9 ± 10 days, and 5 patients died (mortality, 17%). CONCLUSIONS: Despite being uncommon, LGIB in cirrhotic patients is associated with a high mortality rate.
BACKGROUND:Lower gastrointestinal bleeding (LGIB) is a common clinical problem, and may be more prevalent among patients with cirrhosis, especially in the setting of portal hypertension and coagulopathy. However, there is extremely little data available on the subject of LGIB in patients with cirrhosis. Therefore, the primary objective of this study was to better understand the etiology and outcomes of cirrhoticpatients hospitalized with LGIB. MATERIALS AND METHODS: We analyzed 3,735 cirrhoticpatients admitted to the Medical University of South Carolina between January 2011 and September 2018, and identified patients admitted with a primary diagnosis of hematochezia or bright red blood per rectum. RESULTS: Thirty patients with cirrhosis and LGIB were included in the cohort. The mean age was 56 ± 13 years, with 30% women. The mean model of end stage liver disease score was 22, and Child-Pugh (CP) scores were C: 41%, B: 33% and A: 26%. The mean Charlson Comorbidity Index was 5.6. Twenty-four (80%) patients had a clinical decompensating event (hepatic encephalopathy, ascites, esophageal varices); the mean hepatic venous pressure gradient was 14.1 mm Hg (n = 8). In 33% of patients, LGIB was considered significant bleeding that necessitated blood transfusion. The most common cause of LGIB was hemorrhoids (11 patients, 37%), followed by portal hypertensive enteropathy or colopathy (7 patients, 23%). Hemoglobin levels on admission were lower in patients with CP B/C cirrhosis than in those with CP A (P < 0.001). The length of stay was 9 ± 10 days, and 5 patients died (mortality, 17%). CONCLUSIONS: Despite being uncommon, LGIB in cirrhoticpatients is associated with a high mortality rate.
Authors: Rajiv Jalan; Marco Pavesi; Faouzi Saliba; Alex Amorós; Javier Fernandez; Peter Holland-Fischer; Rohit Sawhney; Rajeshwar Mookerjee; Paolo Caraceni; Richard Moreau; Pere Ginès; Francois Durand; Paolo Angeli; Carlo Alessandria; Wim Laleman; Jonel Trebicka; Didier Samuel; Stefan Zeuzem; Thierry Gustot; Alexander L Gerbes; Julia Wendon; Mauro Bernardi; Vicente Arroyo Journal: J Hepatol Date: 2014-11-22 Impact factor: 25.083
Authors: Andreas Blesl; Martin Eibisberger; Michael Schörghuber; Christoph Klivinyi; Vanessa Stadlbauer Journal: J Clin Med Date: 2021-04-29 Impact factor: 4.241